Literature DB >> 13867794

Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806).

D E BERGSAGEL, C C SPRAGUE, C AUSTIN, K M GRIFFITH.   

Abstract

Entities:  

Keywords:  ANTINEOPLASTIC AGENTS/therapy; MYELOMA, PLASMA CELL/therapy

Mesh：

Substances：

Year:  1962        PMID： 13867794

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  22 in total

1.  Multiple myeloma.

Authors:  W A SKOOG; W S ADAMS
Journal:  Calif Med       Date:  1963-08

Review 2.  Multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Curr Probl Cancer       Date:  2009 Jan-Feb       Impact factor: 3.187

3.  Multiple myeloma: biology and therapy.

Authors:  B Barlogie; J Epstein
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

4.  Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents.

Authors:  Junya Kuroda; Yuji Shimura; Kensuke Ohta; Hirokazu Tanaka; Hirohiko Shibayama; Satoru Kosugi; Shinichi Fuchida; Masayuki Kobayashi; Hitomi Kaneko; Nobuhiko Uoshima; Kazuyoshi Ishii; Shosaku Nomura; Masafumi Taniwaki; Akifumi Takaori-Kondo; Chihiro Shimazaki; Mitsuru Tsudo; Masayuki Hino; Itaru Matsumura; Yuzuru Kanakura
Journal:  Int J Hematol       Date:  2014-03-01       Impact factor: 2.490

5.  Proteometabolomics of Melphalan Resistance in Multiple Myeloma.

Authors:  David C Koomen; Joy D Guingab-Cagmat; Paula S Oliveira; Bin Fang; Min Liu; Eric A Welsh; Mark B Meads; Tuan Nguyen; Laurel Meke; Steven A Eschrich; Kenneth H Shain; Timothy J Garrett; John M Koomen
Journal:  Methods Mol Biol       Date:  2019

6.  The effect of 1-phenylalanine mustard on anti-globulin antibodies in multiple myeloma.

Authors:  M Waller; J H Moon; R Irby; E C Toone
Journal:  Clin Exp Immunol       Date:  1971-01       Impact factor: 4.330

7.  Phase II study of carboplatin (CBDCA) in refractory multiple myeloma. A Southwest Oncology Group study.

Authors:  B Barlogie; J Crowley; S E Salmon; J Bonnet; J K Weick; K Hayden
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

Review 8.  Multiple myeloma. New treatment options.

Authors:  L Camba; B G Durie
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

9.  Multiple myeloma. Clinical correlation of immunoglobulin changes with therapy. A report of 23 cases.

Authors:  C M Basch; E H Rosenbaum
Journal:  Calif Med       Date:  1969-01

Review 10.  Multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Blood       Date:  2008-03-15       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.